Skip to main content

Recombinant Human IL-31 (HEK293-expressed) Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10425-IL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
10425-IL-020

Key Product Details

Source

HEK293

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human IL-31 protein
Leu27-Thr164

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu27

Predicted Molecular Mass

16 kDa

SDS-PAGE

19-29 kDa, under reducing conditions

Activity

Recombinant Human IL-31 (HEK293-expressed) (Catalog # 10425-IL) stimulates CCL2/JE/MCP-1 secretion from the BEAS-2B Human lung bronchial epithelial cell line. The ED50 for this effect is <5 ng/mL.

Scientific Data Images for Recombinant Human IL-31 (HEK293-expressed) Protein, CF

Recombinant Human IL-31 (HEK293-expressed) Protein Bioactivity

Recombinant Human IL-31 (HEK293-expressed) Protein Bioactivity

Recombinant Human IL-31 (HEK293-expressed) (10425-IL) stimulates CCL2/JE/MCP-1 secretion from the BEAS-2B Human lung bronchial epithelial cell line. The ED50 for this effect is <5 ng/mL.
Recombinant Human IL-31 (HEK293-expressed) Protein SDS-PAGE

Recombinant Human IL-31 (HEK293-expressed) Protein SDS-PAGE

2 μg/lane of Recombinant Human IL-31 (HEK293-expressed) Protein (Catalog # 10425-IL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 19-29 kDa.

Formulation, Preparation and Storage

10425-IL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 200 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-31

Human Interleukin-31 (IL-31) is a short-chain member of the alpha -helical family of cytokines. The human IL-31 cDNA encodes a 164 amino acid (aa) precursor that contains a signal peptide and a mature protein (1, 2). The mature region shows four alpha -helices which would be expected to show a typical up‑up‑down‑down topology. Human and mouse IL-31 share 24% aa sequence identity in the mature region (1). IL-31 is mainly associated with activated T cells and preferentially expressed by Th2 rather than Th1 cells. IL-31 signals via a heterodimeric receptor complex composed of a 120 kDa, gp130-related molecule termed IL‑31 RA (also GPL and GLM-R) and the 180 kDa oncostatin M receptor (OSM R beta) (2-6). In the complex, IL-31 directly binds to IL-31 RA, not OSM R (2, 3). IL-31 signaling has been shown to involve the Jak/STAT pathway, the PI3 kinase/AKT cascade, and the MAP kinase pathway (2-5). STAT3 is an important factor in MCP-1 (CCL2) regulation in tumor cells, as well as in keratinocytes. Impaired IL-31-induced production of MCP-1 in MT (mutant IL-31RA-S521F) cells is, at least in part, attributed to the much‑reduced STAT3 activation in IL-31 signaling (9). Although multiple isoforms of IL-31 RA are known, only a form that contains the entire length of the cytoplasmic domain is signaling-capable (2, 3). The IL-31 receptor is constitutively expressed by keratinocytes and up‑regulated by IFN-gamma on monocytes (1). Studies using transgenic mice indicate that IL-31 may contribute to the pruritis (itching) associated with nonatopic dermatitis (1, 7). Eccrine sweat is secreted onto the skin's surface and is not harmful to normal skin, but can exacerbate eczematous lesions in atopic dermatitis. IL-31 seems to be a sweat stimulator that activates keratinocytes to produce inflammatory cytokine CCL2 (10). IL-31 (50 ng/ml) could significantly activate the release of EGF, VEGF, CCL2 but not IL-6 and IL-8 from BEAS-2B cells after 18 hr (8).

References

  1. Dillon, S.R. et al. (2004) Nat. Immunol. 5:752.
  2. Diveu, C. et al. (2004) Eur. Cytokine Netw. 15:291.
  3. Dreuw, A. et al. (2004) J. Biol. Chem. 279:36112.
  4. Diveu, C. et al. (2003) J. Biol. Chem. 278:49850.
  5. Ghilardi, N. et al. (2002) J. Biol. Chem 277:16831.
  6. Mosley, B. et al. (1996) J. Biol. Chem. 271:32635.
  7. Takaoka, A. et al. (2005) Eur. J. Pharmacol. 516:180.
  8. Lam, C. et al. (2007) Immunology. 122:532.
  9. Shiao, Y. et al. (2013) J. Invest. Derm. 133:5.
  10. Dai, X. et al. (2013) PLoS One. 8:7.

Long Name

Interleukin 31

Alternate Names

IL31

Entrez Gene IDs

386653 (Human); 76399 (Mouse)

Gene Symbol

IL31

UniProt

Additional IL-31 Products

Product Documents for Recombinant Human IL-31 (HEK293-expressed) Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human IL-31 (HEK293-expressed) Protein, CF

For research use only

Loading...
Loading...
Loading...